Last reviewed · How we verify
Oral steroid - predonisolone
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisolone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Adjunctive treatment in cancer therapy to manage inflammation and side effects, Lymphoproliferative disorders, Autoimmune complications in cancer patients.
At a glance
| Generic name | Oral steroid - predonisolone |
|---|---|
| Sponsor | Instituto do Cancer do Estado de São Paulo |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | FDA-approved |
Mechanism of action
Prednisolone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. The drug is commonly used in oncology as an adjunctive agent to manage treatment-related inflammation and as part of combination chemotherapy regimens.
Approved indications
- Adjunctive treatment in cancer therapy to manage inflammation and side effects
- Lymphoproliferative disorders
- Autoimmune complications in cancer patients
Common side effects
- Hyperglycemia
- Immunosuppression / increased infection risk
- Osteoporosis
- Hypertension
- Gastrointestinal upset
- Insomnia
- Mood changes
Key clinical trials
- Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral steroid - predonisolone CI brief — competitive landscape report
- Oral steroid - predonisolone updates RSS · CI watch RSS
- Instituto do Cancer do Estado de São Paulo portfolio CI